HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies.

Coyle D, Durand-Zaleski I, Farrington J, Garrison L, Graf von der Schulenburg J-M, Greiner W, Longworth L, Meunier A, Moutie A-S, Palmer S, Pemberton-Whiteley Z, et al. (2020)
The European journal of health economics : HEPAC : health economics in prevention and care.

Zeitschriftenaufsatz | E-Veröff. vor dem Druck | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Coyle, Doug; Durand-Zaleski, Isabelle; Farrington, Jasmine; Garrison, Louis; Graf von der Schulenburg, Johann-Matthias; Greiner, WolfgangUniBi; Longworth, Louise; Meunier, Aurelie; Moutie, Anne-Sophie; Palmer, Stephen; Pemberton-Whiteley, Zack; Ratcliffe, Mark
Alle
Abstract / Bemerkung
This last decade has been marked by significant advances in the development of cell and gene (C&G) therapies, such as gene targeting or stem cell-based therapies. C&G therapies offer transformative benefits to patients but present a challenge to current health technology decision-making systems because they are typically reviewed when clinical efficacy data are very limited and when there is uncertainty about the long-term durability of outcomes. These challenges are not unique to C&G therapies, but they face more of these barriers, reflecting the need for adapting existing value assessment frameworks. Still, C&G therapies have the potential to be cost-effective even at very high price points. The impact on healthcare budgets will depend on the success rate of pipeline assets and on the extent to which C&G therapies will expand to wider pathologies beyond rare or ultra-rare diseases. Getting pricing and reimbursement models right is important for incentivising research and development investment while not jeopardising the sustainability of healthcare systems. Payers and manufacturers therefore need to acknowledge each other's constraints-limitations in the evidence generation on the manufacturer side, budget considerations on the payer side-and embrace innovative thinking and approaches to ensure timely delivery of therapies to patients. Several experts in health technology assessment and clinical experts have worked together to produce this publication and identify methodological and policy options to improve the assessment of C&G therapies, and make it happen better, faster and sustainably in the coming years.
Erscheinungsjahr
2020
Zeitschriftentitel
The European journal of health economics : HEPAC : health economics in prevention and care
eISSN
1618-7601
Page URI
https://pub.uni-bielefeld.de/record/2945526

Zitieren

Coyle D, Durand-Zaleski I, Farrington J, et al. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. The European journal of health economics : HEPAC : health economics in prevention and care. 2020.
Coyle, D., Durand-Zaleski, I., Farrington, J., Garrison, L., Graf von der Schulenburg, J. - M., Greiner, W., Longworth, L., et al. (2020). HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. The European journal of health economics : HEPAC : health economics in prevention and care. doi:10.1007/s10198-020-01212-w
Coyle, D., Durand-Zaleski, I., Farrington, J., Garrison, L., Graf von der Schulenburg, J. - M., Greiner, W., Longworth, L., Meunier, A., Moutie, A. - S., Palmer, S., et al. (2020). HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. The European journal of health economics : HEPAC : health economics in prevention and care.
Coyle, D., et al., 2020. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. The European journal of health economics : HEPAC : health economics in prevention and care.
D. Coyle, et al., “HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies.”, The European journal of health economics : HEPAC : health economics in prevention and care, 2020.
Coyle, D., Durand-Zaleski, I., Farrington, J., Garrison, L., Graf von der Schulenburg, J.-M., Greiner, W., Longworth, L., Meunier, A., Moutie, A.-S., Palmer, S., Pemberton-Whiteley, Z., Ratcliffe, M., Shen, J., Sproule, D., Zhao, K., Shah, K.: HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. The European journal of health economics : HEPAC : health economics in prevention and care. (2020).
Coyle, Doug, Durand-Zaleski, Isabelle, Farrington, Jasmine, Garrison, Louis, Graf von der Schulenburg, Johann-Matthias, Greiner, Wolfgang, Longworth, Louise, Meunier, Aurelie, Moutie, Anne-Sophie, Palmer, Stephen, Pemberton-Whiteley, Zack, Ratcliffe, Mark, Shen, Jie, Sproule, Doug, Zhao, Kun, and Shah, Koonal. “HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies.”. The European journal of health economics : HEPAC : health economics in prevention and care (2020).

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 32794011
PubMed | Europe PMC

Suchen in

Google Scholar